Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.

The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma (NHL) in therapeutic trials. We undertook this study to determine whether this regimen would be effective and tolerable in Korean patients. A total of 40 patients ...

iev (ifosfamide, epirubicin, vp16) regimen as salvage therapy for early relapsed/refractory non-hodgkin/hodgkin lymphoma

introduction: management of early relapsed or refractory lymphoma [hodgkin & non- hodgkin lymphoma (hl & nhl)] is a matter of problem, especially when hematopietic stem cell support is not available. the aim of this study was to evaluate effectiveness of iev regimen ( ifosfamide, epirubicin, vp16), in lymphoma patients who are not candidate for stem cell transplantation. because the majority of...

Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas.

BACKGROUND AND OBJECTIVE Patients with follicular lymphoma (FL) who do not respond to first-line chemotherapy or those who relapse after obtaining a remission have a poor outcome with standard treatment. In an effort to obtain a high rate of responses we designed an intensive brief duration salvage chemotherapy regimen. DESIGN AND METHODS Forty-four consecutive patients with advanced follicul...

Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab.

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience

BACKGROUND The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to determine whether ESHAP therapy would be effective and well-tolerated in Korean patients. METHODS Twenty two patient...